Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 4/20 | 0.41 |
| ▸ | FNTB | P49356 | 4/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295517 | 0.82 | IDH1 (0.43) | MAP3K8CYP11B1CYP11B2FNTAFNTB | |
| SCHEMBL7049602 | 0.81 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL17295201 | 0.80 | MAP3K8 (0.49) | MAP3K8 | |
| SCHEMBL17295270 | 0.75 | KDM4E (0.40) | CYP11B2CACNA1B | |
| SCHEMBL7572173 | 0.73 | FNTA (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL15133290 | 0.72 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL46652 | 0.71 | — | — | |
| SCHEMBL3638724 | 0.71 | FRK (0.44) | MAP3K8 | |
| SCHEMBL7572286 | 0.71 | FNTA (0.57) | FNTAFNTBPGGT1B | |
| SCHEMBL7446567 | 0.71 | TRPM5 (0.51) | CYP11B1CYP11B2CACNA1BCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | MAP3K8 2802/4885CYP11B1 3329/4885CYP11B2 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.